Amber Gordon
Impact in
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 10
- Chronic Lymphocytic Leukemia Research 10
-
- PI3K/AKT/mTOR signaling in cancer 3
- Glycosylation and Glycoproteins Research 1
- Co-authors
- John C. Byrd (13 shared papers)Amy J. Johnson (7 shared papers)Joseph M. Flynn (4 shared papers)Sarah E. M. Herman (4 shared papers)Jeffrey J. Jones (2 shared papers)Kristie A. Blum (4 shared papers)Asha Ramanunni (2 shared papers)Xiaoli Zhang (2 shared papers)
- Journals
- Blood (8 papers)Haematologica (2 papers)Journal of Clinical Oncology (1 paper)Journal of Clinical Investigation (1 paper)Leukemia & lymphoma (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Amber Gordon
14 papers receiving 1.5k citations
Amber Gordon's Hit Papers
Peers
Comparison fields: 5 of 52
- Genetics 1.1k
- Pathology and Forensic Medicine 689
- Hematology 324
- Immunology 472
- Oncology 306
Countries citing papers authored by Amber Gordon
This map shows the geographic impact of Amber Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber Gordon more than expected).
Fields of papers citing papers by Amber Gordon
This network shows the impact of papers produced by Amber Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber Gordon. The network helps show where Amber Gordon may publish in the future.
Co-authors
The 25 scholars most cited alongside Amber Gordon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Hit paper breakdown → | 2011 | 610 |
| 2 | 2010 | 435 | |
| 3 | 2017 | 294 | |
| 4 | 2011 | 82 | |
| 5 | 2018 | 33 | |
| 6 | 2012 | 14 | |
| 7 | 2014 | 9 | |
| 8 | 2020 | 7 | |
| 9 | 2010 | 3 | |
| 10 | Anatomy, Shoulder and Upper Limb, Axilla | 2019 | 2 |
| 11 | 2016 | 1 | |
| 12 | 2016 | 1 | |
| 13 | 2014 | 1 | |
| 14 | 2016 | 1 |
About Amber Gordon
Amber Gordon is a scholar working on Genetics, Molecular Biology, Pathology and Forensic Medicine, Immunology and Hematology, having authored 14 papers that have together received 1.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Chronic Myeloid Leukemia Treatments (2 papers), Toxin Mechanisms and Immunotoxins (2 papers), Multiple Myeloma Research and Treatments (2 papers), Immunodeficiency and Autoimmune Disorders (2 papers) and Glycosylation and Glycoproteins Research (1 paper). The work is most often cited by research in Genetics (1.1k citations), Pathology and Forensic Medicine (689 citations), Hematology (324 citations), Immunology (472 citations) and Oncology (306 citations). Amber Gordon has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include John C. Byrd, Amy J. Johnson, Joseph M. Flynn, Sarah E. M. Herman, Jeffrey J. Jones, Kristie A. Blum, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski and Erin Hertlein. Their work appears in journals such as Blood, Haematologica, Journal of Clinical Oncology, Journal of Clinical Investigation and Leukemia & lymphoma.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.